pyrazines has been researched along with Lymphoma, T Cell, Peripheral in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Colvin, J; Evens, AM; Gordon, LI; Helenowski, I; Kline, J; Larsen, A; Rosen, ST; Smith, SM; van Besien, KM; Winter, JN | 1 |
| Chen, SJ; Guo, Y; Janin, A; Leboeuf, C; Romero, M; Wang, L; Wu, LL; Xue, K; Yan, ZX; Zhang, QL; Zhao, WL | 1 |
| Brown, RE; Nguyen, ND; Quesada, AE; Rios, A | 1 |
| Bazarbachi, A; Hatoum, HA; Mahfouz, RA; Otrock, ZK; Salem, ZM; Tawil, A; Zaatari, GS | 1 |
| Cheson, BD | 1 |
| O'Connor, OA | 1 |
| Ang, AL; Goh, YT; Mok, SJ; Phipps, C; Tan, D | 1 |
| Do, IG; Huh, J; Kang, HJ; Kim, HJ; Kim, HK; Kim, JS; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, SS; Min, SK; Park, SK; Ryoo, BY; Suh, C; Yang, WI; Yoon, DH | 1 |
2 review(s) available for pyrazines and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
Novel therapies for peripheral T-cell non-Hodgkin's lymphomas.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Cladribine; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Lymphoma, T-Cell, Peripheral; Nitrogen Mustard Compounds; Pyrazines; Vidarabine | 2009 |
Novel agents in development for peripheral T-cell lymphoma.
Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Depsipeptides; Drug Design; Drugs, Investigational; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Purine Nucleosides; Pyrazines; Pyrimidinones; Salvage Therapy; Thalidomide | 2010 |
2 trial(s) available for pyrazines and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Pyrazines; Recurrence; Treatment Outcome | 2013 |
Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Staging; NF-kappa B; Prednisone; Pyrazines; Vincristine | 2012 |
4 other study(ies) available for pyrazines and Lymphoma, T Cell, Peripheral
| Article | Year |
|---|---|
MicroRNA187 overexpression is related to tumor progression and determines sensitivity to bortezomib in peripheral T-cell lymphoma.
Topics: Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma, T-Cell, Peripheral; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Pyrazines | 2014 |
Expression of constitutively activated NF-κB/mTORC pathway proteins and response to CHOP with bortezomib in a patient with angioimmunoblastic peripheral T-cell lymphoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, T-Cell, Peripheral; NF-kappa B; Positron-Emission Tomography; Prednisone; Pyrazines; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Burden; Vincristine | 2014 |
Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Doxorubicin; Fatal Outcome; Female; Humans; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Prednisone; Protease Inhibitors; Pyrazines; Remission Induction; T-Lymphocyte Subsets; Transplantation, Autologous; Vincristine | 2008 |
Bortezomib and panobinostat combination is effective against PTCL.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Hydroxamic Acids; Indoles; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Multimodal Imaging; Panobinostat; Positron-Emission Tomography; Pyrazines; Tomography, X-Ray Computed; Treatment Outcome | 2012 |